Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vinorelbine Tartrate

FDA-approved product (injectable, injection), marketed as Navelbine, Vinorelbine Tartrate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Vinorelbine Tartrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vinorelbine Tartrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vinorelbine Tartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

    NCT01126138 · start 2010-07

    Registered record
    Registry ID
    NCT01126138
    Conditions
    Carcinoma, Invasive Ductal, Breast
    Interventions
    Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine; Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2010-07
    Completion
    2015-08
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Invasive Ductal, Breast
    InterventionVinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine; Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
    PhasePhase 3
    Registry statusUnknown

  • Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

    NCT01007942 · start 2009-10

    Registered record
    Registry ID
    NCT01007942
    Conditions
    HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
    Interventions
    everolimus; Placebo; vinorelbine; trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10
    Completion
    2015-06
    Enrolment
    569

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
    Interventioneverolimus; Placebo; vinorelbine; trastuzumab
    PhasePhase 3
    Registry statusCompleted

  • Lapatinib in Combination With Vinorelbine

    NCT01128543 · start 2009-04

    Registered record
    Registry ID
    NCT01128543
    Conditions
    Cancer
    Interventions
    lapatinib and Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-04
    Completion
    2012-03
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    Interventionlapatinib and Vinorelbine
    PhasePhase 2
    Registry statusCompleted

  • A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

    NCT00643565 · start 2008-07-29

    Registered record
    Registry ID
    NCT00643565
    Conditions
    Sarcoma
    Interventions
    Standard chemotherapy; bevacizumab [Avastin]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-07-29
    Completion
    2019-04-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    InterventionStandard chemotherapy; bevacizumab [Avastin]
    PhasePhase 2
    Registry statusCompleted

  • Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

    NCT00920153 · start 2008-05

    Registered record
    Registry ID
    NCT00920153
    Conditions
    Lymphoma
    Interventions
    bleomycin sulfate; ABVD regimen; carmustine; cisplatin; cytarabine; dacarbazine; dexamethasone; doxorubicin hydrochloride; etoposide; gemcitabine hydrochloride; ifosfamide; melphalan; methylprednisolone; mitoguazone; vincristine sulfate; vindesine; vinorelbine tartrate; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-05
    Completion
    2016-03
    Enrolment
    442

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionbleomycin sulfate; ABVD regimen; carmustine; cisplatin +15 more
    PhasePhase 3
    Registry statusTerminated

  • Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

    NCT00379457 · start 2006-06

    Registered record
    Registry ID
    NCT00379457
    Conditions
    Sarcoma
    Interventions
    dactinomycin; carboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide; ifosfamide; topotecan hydrochloride; vincristine sulfate; vinorelbine tartrate; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-06
    Completion
    Not recorded
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiondactinomycin; carboplatin; cyclophosphamide; doxorubicin hydrochloride +7 more
    PhasePhase 3
    Registry statusUnknown

  • Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer

    NCT01439191 · start 2005-07

    Registered record
    Registry ID
    NCT01439191
    Conditions
    Metastatic Breast Cancer
    Interventions
    humanized anti-HER2 antibody; Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-07
    Completion
    2007-05
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    Interventionhumanized anti-HER2 antibody; Vinorelbine
    PhasePhase 2
    Registry statusCompleted

  • Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

    NCT00111839 · start 2005-05-31

    Registered record
    Registry ID
    NCT00111839
    Conditions
    Lung Cancer; Non Small Cell Lung Carcinoma
    Interventions
    Pemetrexed; Matuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-05-31
    Completion
    2009-03-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Non Small Cell Lung Carcinoma
    InterventionPemetrexed; Matuzumab
    PhasePhase 2
    Registry statusCompleted

  • Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

    NCT00083083 · start 2005-03

    Registered record
    Registry ID
    NCT00083083
    Conditions
    Lung Cancer
    Interventions
    carboplatin; cisplatin; docetaxel; etoposide; paclitaxel; vinblastine sulfate; vinorelbine tartrate; gene expression analysis; positron emission tomography; fludeoxyglucose F 18; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2005-03
    Completion
    Not recorded
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventioncarboplatin; cisplatin; docetaxel; etoposide +7 more
    PhasePhase 2
    Registry statusUnknown

  • Phase II Iressa Versus Vinorelbine (INVITE)

    NCT00256711 · start 2004-07

    Registered record
    Registry ID
    NCT00256711
    Conditions
    Non-Small-Cell Lung Carcinoma
    Interventions
    Gefitinib; Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-07
    Completion
    2006-02
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Carcinoma
    InterventionGefitinib; Vinorelbine
    PhasePhase 2
    Registry statusCompleted

  • Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

    NCT00287963 · start 2004-02

    Registered record
    Registry ID
    NCT00287963
    Conditions
    Lung Cancer
    Interventions
    topotecan hydrochloride; vinorelbine tartrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-02
    Completion
    2010-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventiontopotecan hydrochloride; vinorelbine tartrate
    PhasePhase 1
    Registry statusCompleted

  • Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

    NCT00194779 · start 2003-10

    Registered record
    Registry ID
    NCT00194779
    Conditions
    Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer
    Interventions
    doxorubicin hydrochloride; cyclophosphamide; paclitaxel; filgrastim; capecitabine; methotrexate; vinorelbine tartrate; needle biopsy; therapeutic conventional surgery; immunohistochemistry staining method; trastuzumab; tamoxifen citrate; letrozole; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-10
    Completion
    2011-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer +5 more
    Interventiondoxorubicin hydrochloride; cyclophosphamide; paclitaxel; filgrastim +10 more
    PhasePhase 2
    Registry statusCompleted

  • Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients

    NCT00271271 · start 2003-06

    Registered record
    Registry ID
    NCT00271271
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    oxaliplatine / gemcitabine / Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-06
    Completion
    2006-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    Interventionoxaliplatine / gemcitabine / Vinorelbine
    PhasePhase 2
    Registry statusCompleted

  • Efficacy Study of Outpatient Therapy for Lymphoma

    NCT00163761 · start 2002-12

    Registered record
    Registry ID
    NCT00163761
    Conditions
    Non-Hodgkin's Lymphoma; Hodgkin's Disease
    Interventions
    gemcitabine, vinorelbine, ifosfamide, filgastrim; gemcitabine, vinorelbine, filgastrim
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-12
    Completion
    2008-02
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Hodgkin's Lymphoma; Hodgkin's Disease
    Interventiongemcitabine, vinorelbine, ifosfamide, filgastrim; gemcitabine, vinorelbine, filgastrim
    PhasePhase 2
    Registry statusCompleted

  • S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

    NCT00041067 · start 2002-09

    Registered record
    Registry ID
    NCT00041067
    Conditions
    Breast Cancer
    Interventions
    filgrastim; trastuzumab; docetaxel; vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09
    Completion
    2012-01
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionfilgrastim; trastuzumab; docetaxel; vinorelbine
    PhasePhase 2
    Registry statusCompleted